Medicare and weight-loss drugs have a complicated relationship, but a 2024 change opened a specific door for Wegovy coverage. The catch is that it depends entirely on why the drug is prescribed.
Quick answer: Medicare does not cover Wegovy for weight loss alone, because Part D excludes drugs used solely for weight loss by law. However, after the FDA approved Wegovy in 2024 to reduce the risk of heart attack, stroke, and cardiovascular death in adults with established cardiovascular disease who are overweight or obese, CMS guidance allows Part D plans to cover Wegovy for that cardiovascular indication. Coverage requires your plan to list it, may involve prior authorization and cost-sharing, and in 2025 Part D caps out-of-pocket drug costs at $2,000. It is covered for the heart indication, not for weight loss.
Does Medicare cover Wegovy in 2025?
It depends on the reason for the prescription. Medicare Part D cannot cover Wegovy when it is prescribed purely for weight loss, because federal law excludes weight-loss drugs from Part D. But in 2025, Wegovy can be covered when prescribed for its approved cardiovascular use, reducing the risk of major cardiovascular events in adults with established heart disease who are overweight or obese. So the same drug may be covered or not covered depending on the documented indication. For people who qualify on the heart-health basis, coverage became possible after the 2024 FDA approval and subsequent CMS guidance.
Why the cardiovascular indication matters
In 2024, the FDA approved Wegovy to reduce the risk of cardiovascular death, heart attack, and stroke in adults who have established cardiovascular disease and are overweight or obese. CMS then clarified that an anti-obesity medication gaining an additional medically accepted indication, like this cardiovascular use, can be treated as a Part D drug for that specific purpose. That guidance is what allows Medicare Part D plans to cover Wegovy, but only for the cardiovascular indication, not for weight management on its own. It is a narrow but meaningful opening for eligible patients.
Medicare and Wegovy: coverage at a glance
| Situation | Medicare Part D coverage |
|---|---|
| Wegovy for weight loss only | Not covered (excluded by law) |
| Wegovy for approved cardiovascular use | May be covered if on plan formulary |
| Prior authorization | Often required |
| 2025 out-of-pocket cap | $2,000 per year for Part D drugs |
| Depends on plan? | Yes, the plan must list it |
What does coverage actually look like?
Even when you qualify on the cardiovascular basis, coverage is not automatic. Your specific Part D or Medicare Advantage plan must include Wegovy on its formulary, and you may face prior authorization, where your prescriber documents that you meet the cardiovascular criteria. Cost-sharing applies, which can be substantial for a specialty-tier drug, though the 2025 Part D design caps your annual out-of-pocket drug spending at $2,000. So eligible patients can still face meaningful costs up to that cap, after which Part D covers the rest for the year.
See transparent compounded pricing
Review compounded GLP-1 pricing and what provider-reviewed care includes, with no surprises at checkout.
Try the Cost Calculator →Who qualifies for Medicare coverage of Wegovy?
The relevant group is adults enrolled in Medicare Part D who have established cardiovascular disease and are overweight or obese, for whom Wegovy is prescribed to reduce cardiovascular risk. People seeking Wegovy purely to lose weight, without that qualifying heart condition, are not covered by Medicare. Your prescriber determines whether you meet the clinical criteria and documents the indication. If you think you may qualify, ask your prescriber and check your plan's formulary and prior-authorization rules.
What if Medicare will not cover it?
If you do not qualify on the cardiovascular basis, or your plan does not list Wegovy, you still have options. Novo Nordisk's NovoCare self-pay program offers cash pricing far below the list price. Compounded semaglutide from licensed pharmacies is another lower-cost route, in a separate category from branded Wegovy. FormBlends connects patients with licensed US pharmacies for compounded semaglutide and tirzepatide; see our provider comparison tool or semaglutide options.
Frequently asked questions
Will Medicare pay for Wegovy in 2025? Only for the approved cardiovascular indication, not for weight loss alone.
Why does Medicare exclude Wegovy for weight loss? Federal law excludes drugs used solely for weight loss from Part D coverage.
What changed in 2024? The FDA approved Wegovy to reduce cardiovascular risk, and CMS guidance allowed Part D coverage for that use.
Do I need prior authorization? Often yes; your prescriber must document that you meet the cardiovascular criteria.
Is there an out-of-pocket cap? Yes. In 2025, Part D caps annual out-of-pocket drug costs at $2,000.
Who qualifies? Adults with established cardiovascular disease who are overweight or obese, prescribed Wegovy to reduce heart risk.
What if I do not qualify? Consider the NovoCare self-pay program or compounded semaglutide from licensed pharmacies.
Sources
- KFF on Medicare coverage of Wegovy: https://www.kff.org/medicare/a-new-use-for-wegovy-opens-the-door-to-medicare-coverage-for-millions-of-people-with-obesity/
- HHS ASPE, Medicare coverage of anti-obesity medications: https://aspe.hhs.gov/sites/default/files/documents/127bd5b3347b34be31ac5c6b5ed30e6a/medicare-coverage-anti-obesity-meds.pdf
Talk to a licensed provider
Start your free assessment. A licensed provider reviews every request before anything is prescribed, and not everyone qualifies.
Start the assessment →